The objective of this application is to examine if combining ionizing radiation with an oncolytic virus SVV-001 would lead to synergistically enhanced tumor cell killing and significantly improve therapeutic efficacy in vivo in patient tumor-derived intra-brainstem xenograft mouse models of diffuse intrinsic pontine glioma (DIPG).
DIPG is the most lethal childhood cancer, and virtually all children with this disease die within 1-2 years of diagnosis. Traditional challenges for the development of new therapies include the lack of clinically relevant animal model systems, difficulties of drug delivery across the blood brain barrier (BBB) and limited options of targeting therapy-resistant tumor cells. Fortunately, we have established a panel of nine orthotopic xenograft mouse models of DIPG in the brain stems of SCID mice. Thanks to the generous support of the Cure Starts Now Foundation, we have completed a research project entitled “Eliminating therapy resistant DIPGs with oncolytic picornavirus SVV-001” and identified Seneca Valley Virus (SVV-001) as an attractive agent for DIPGs. Our data confirmed that SVV-001 can infect and effectively kill DIPG tumor cells in vitro, and pass through the BBB in vivo, leading to improved animal survival in a subset of intra-brain stem DIPG xenograft models. However, when compared with greater than 80% cell killing in vitro, the animal survival time was only prolonged~10% (P <0.05), indicating the limited efficiency of SVV-001 as a single agent.
To address such response discrepancies between the i nvitro and in vivo activities and to see knew strategies to further improve therapeutic efficacy, we examined the cellular content of mitochondria, which is the recognized assembly station of many viruses 1-6. We found that mitochondria were very rich in the cultured DIPG cells, but scarce in many xenograft tumor cells derived from the same models. This has led us to hypothesize that the lack of mitochondria in the xenograft tumor cells in vivo impaired the intracellular replication of SVV-001 and subsequently weakened the oncolytic cell killing of the target tumor cells. Fortunately, we have found that ionizing radiation can activate robust mitochondrial biogenesis in vivo, converting mitochondrial-depleted tumor cells to mitochondria-rich tumor cells. Indeed, our preliminary studies involving pediatric GBM have shown that combining fractionated radiation (2 Gy/day for 5 days) with single i.v. injection of SVV-001 led to significant improvement of animal survival times. Since many of the DIPG tumor cells were shown to be responsive to SVV-001 in vitro (they may therefore be inherently permissive to SVV-001), it is therefore our second hypothesis that radiation induced increase of mitochondria would provide SVV-001 the much needed replication “facilities”, thereby converting the “dormant” tumor cells into responsive tumor cells that can be killed. To test these hypotheses, we will utilize our established orthotopic xenograft mouse models to accomplish the following Specific Aims: 1) To prove that lack of mitochondria causes SVV001 resistance in the permissive DIPG tumor cells in vivo; 2) To demonstrate that ionizing radiation activates mitochondrial biogenesis in previously mitochondria-deficient/depleted tumor cells and sensitizes them to SVV-001 induced cell death; 3) To demonstrate that combining ionizing radiation with intravenously injected SVV-001 can improve therapeutic efficacy in vivo, leading to significantly improved animal survival.
The innovations of our proposed studies are two fold. First, it lies in our novel use of a relatively large panel of intra-brain stem DIPG xenograft mouse models. These models were derived from terminal stage DIPG patients and represent the clinically proven therapy-resistant DIPGs that are in desperate need of new therapies. Our models have provided us with unprecedented opportunities to study the biology and to test new therapies in vivo in a micro environment that is the closest to human DIPGs. Secondly, it lies in our prospective examination of the therapeutic efficacy of a novel combined treatment that is rationally designed based on the molecular mechanisms that are complementary to each other. SVV-001 has many features that make it particularly attractive for brain tumors. Identifying the underlying mechanism of SVV-001 resistance and the subsequent development of a new strategy to overcome such resistance would prevent the premature drop-out of a potentially effective therapy. More importantly, since our approach is built on the top of radiotherapy, the standard treatment for DIPGs, our chances of rapid translation into clinical trials are therefore greatly improved.
Theobjective of thisapplicationistoexamineifcombiningionizingradiationwithan oncolyticvirusSVV-001 would lead to synergistically enhanced tumor cell killing and significantly improve therapeutic efficacyin vivo inpatienttumor-derivedintra-brainstemxenograftmousemodelsofdiffuseintrinsicpontineglioma(DIPG).
DIPG is the most lethal childhood cancer, and virtuallyall children with this disease die within 1-2 years of diagnosis. Traditional challenges for the development of new therapies include the lack of clinically relevant animal model systems, difficulties of drug delivery across the blood brain barrier (BBB) and limited options of targeting therapy-resistant tumor cells. Fortunately, we have established a panel of nine orthotopic xenograft mouse models of DIPG in the brain stems of SCID mice. Thanks to the generous support of the Cure Starts Now Foundation, we have completed a research project entitled “Eliminating therapy resistant DIPGs with oncolytic picornavirus SVV-001” and identified Seneca Valley Virus (SVV-001) as an attractive agent for DIPGs. Our data confirmed that SVV-001 can infect and effectively kill DIPG tumor cells in vitro, and pass through the BBB in vivo, leading to improved animal survival in a subset of intra-brain stem DIPG xenograft models. However, when compared with greater than80% cellkillinginvitro,theanimalsurvivaltime wasonly prolonged~10%(P <0.05),indicatingthelimitedefficiencyofSVV-001asasingleagent.
Toaddress suchresponse discrepanciesbetweenthe invitroandinvivoactivitiesandtoseeknewstrategies to further improve therapeutic efficacy, we examined the cellular content of mitochondria, which is the recognized assembly station of many viruses1-6. We found that mitochondria were very rich in the cultured DIPG cells, but scarce in many xenograft tumor cells derived from the same models. This has led us to hypothesize that the lack of mitochondria in the xenograft tumor cells in vivo impaired the intracellular replication of SVV-001 and subsequently weakened the oncolytic cell killing of the target tumor cells. Fortunately, we have found that ionizing radiation can activate robust mitochondrial biogenesis in vivo, convertingmitochondrial-depleted tumor cells to mitochondria-rich tumor cells. Indeed, our preliminarystudies involving pediatric GBM have shown that combining fractionated radiation (2 Gy/day for 5 days) with single i.v. injection of SVV-001 led to significant improvement of animal survival times. Since many of the DIPG tumor cells were shown to be responsive to SVV-001 in vitro (they may therefore be inherently permissive to SVV-001), it is therefore our second hypothesis that radiation induced increase of mitochondria would provide SVV-001themuchneededreplication“facilities”,therebyconvertingthe“dormant”tumorcellsintoresponsive tumor cells that can be killed. To test these hypotheses, we will utilize our established orthotopic xenograft mouse models to accomplish the following Specific Aims: 1) To prove that lack of mitochondria causes SVV001 resistance in the permissive DIPG tumor cells in vivo; 2) To demonstrate that ionizing radiation activates mitochondrial biogenesis in previously mitochondria-deficient/depleted tumor cells and sensitizes them to SVV-001 induced cell death; 3) To demonstrate that combining ionizing radiation with intravenously injected SVV-001canimprovetherapeuticefficacyinvivo,leadingtosignificantlyimprovedanimalsurvival.
The innovations of our proposed studies are two fold. First, it lies in our novel use of a relativelylarge panel of intra-brain stem DIPG xenograft mouse models. These models were derived from terminal stage DIPG patients and represent the clinicallyproven therapy-resistant DIPGs that are in desperate need of new therapies. Our modelshaveprovideduswithunprecedented opportunitiestostudythe biologyand totest newtherapies in vivo ina microenvironment thatis theclosest tohuman DIPGs. Secondly, it liesinourprospective examination of the therapeutic efficacy of a novel combined treatment that is rationally designed based on the molecular mechanisms that are complementary to each other. SVV-001 has many features that make it particularly attractive for brain tumors. Identifying the underlying mechanism of SVV-001 resistance and the subsequent development of a new strategy to overcome such resistance would prevent the premature drop-out of a potentially effective therapy. More importantly, since our approach is built on the top of radiotherapy, the standardtreatmentforDIPGs,ourchancesofrapidtranslationintoclinicaltrialsarethereforegreatlyimproved.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer gravida non felis non euismod. Fusce finibus aliquet consequat. Nam ac metus bibendum, iaculis purus sed, suscipit ligula. Proin et nisi libero. Mauris non urna urna. Nullam augue eros, fringilla sed mauris vitae, porta tincidunt risus. Aliquam sed tincidunt sem. Quisque lacinia quam tortor, imperdiet efficitur odio iaculis in. Sed ultricies condimentum volutpat. Vivamus dignissim faucibus porta.
Curabitur ut ipsum non odio malesuada vulputate. Morbi maximus, est eu lobortis molestie, tortor sapien hendrerit nisi, in cursus odio diam ut odio. Fusce pulvinar volutpat velit. Aliquam erat volutpat. Integer rhoncus mollis suscipit. Praesent non ipsum mollis, finibus nunc a, scelerisque nibh. In feugiat iaculis velit, eu semper lacus dignissim nec. Praesent vitae nisi leo. Cras venenatis dictum magna ut semper. Sed eget eros nibh. Sed vitae quam sed dolor faucibus elementum. Curabitur interdum porttitor finibus. Nullam tincidunt odio lectus, sit amet rhoncus libero dapibus sed. Sed mollis egestas enim, vel porta tortor volutpat eget.
Morbi orci urna, ornare non pretium eget, pulvinar eget magna. Ut consectetur efficitur varius. Fusce ac aliquet mauris, at mattis ligula. Quisque est libero, interdum id orci et, ornare luctus diam. Proin commodo lectus id accumsan blandit. Nulla eu turpis interdum, luctus ante ac, imperdiet tellus. In semper enim eu tristique aliquam.
Integer fermentum vestibulum lacinia. Duis id aliquam nibh, ut mattis leo. Nulla ac dui at sapien posuere facilisis ut quis ex. Aliquam vestibulum blandit tristique. Integer pretium dui ac nulla accumsan, et finibus velit euismod. Proin placerat, nunc eu sodales facilisis, tellus justo efficitur risus, non blandit diam nulla ac ligula. Aliquam ullamcorper quam leo, porttitor dictum ex tempor ac. Ut efficitur, justo et auctor volutpat, ex ex pulvinar est, sed consequat turpis leo nec ipsum. Nunc tempor, turpis ut ullamcorper tempor, dolor dui varius dui, et congue quam nisi vel nunc.
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Donec faucibus, turpis sit amet maximus dapibus, sapien nisl bibendum turpis, pharetra commodo tellus libero vel nulla. Sed nec velit viverra, congue sapien et, gravida libero. Proin eget ante eget turpis egestas accumsan. Aliquam arcu nibh, aliquam rhoncus vulputate in, pellentesque at sem. Maecenas cursus tempus nibh id tempus. Mauris dolor sapien, lacinia sit amet condimentum at, dapibus eget lectus. Phasellus vel pellentesque ex. Nunc aliquam in ligula at tristique. In mollis suscipit felis eu finibus. Nullam non dignissim nibh, nec suscipit ex. Suspendisse tincidunt et mauris id finibus. Aliquam vehicula a sem quis venenatis.
Suspendisse leo odio, rutrum et viverra ut, consequat finibus enim. Vivamus dolor nisl, viverra eu egestas vel, blandit in nulla. Curabitur auctor purus non est volutpat bibendum. Proin fringilla magna sed metus maximus, in dictum neque suscipit. Sed ornare ut mi ut sodales. Nulla efficitur urna nunc, non molestie nunc egestas ut. Nunc arcu lorem, semper ut tincidunt ac, eleifend quis elit.
Sed at tortor et tortor tincidunt feugiat id in dui. Vivamus eget justo nisl. Aenean congue laoreet nisl a elementum. Nunc consectetur velit non ligula sollicitudin, quis eleifend urna sollicitudin. Sed tincidunt, nisl quis varius venenatis, dui massa condimentum tellus, sed sollicitudin diam magna mollis augue. Sed venenatis commodo purus id malesuada. Aenean volutpat elit vel gravida consectetur. Vestibulum diam quam, lacinia ac tortor eget, tincidunt dapibus dui. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin nisl leo, pretium sed arcu imperdiet, hendrerit sollicitudin sem. Duis non magna at nunc sagittis ullamcorper a id est. Maecenas cursus nisl in faucibus hendrerit.
Sed hendrerit vitae purus et tempor. Aenean vitae varius velit. Nullam aliquet ipsum elit. Mauris vestibulum purus et metus imperdiet, quis gravida eros pretium. Curabitur rutrum nunc vitae tincidunt condimentum. Aenean sit amet augue velit. Nunc tristique quis lorem id pharetra. Pellentesque sollicitudin, eros sed egestas rutrum, nulla nisl sodales elit, ut imperdiet nunc lectus sit amet nulla. Ut malesuada finibus libero. Curabitur mi dolor, sollicitudin quis bibendum quis, dictum sed enim.
Pellentesque nibh erat, egestas sit amet sagittis malesuada, rhoncus at neque. Mauris maximus commodo tortor, non egestas magna finibus vitae. Sed hendrerit nulla vel venenatis tempor. Suspendisse tristique tincidunt libero et placerat. Nam tincidunt condimentum lorem, vel pharetra est iaculis sed. Nullam ac tincidunt orci. Quisque pharetra ut sem sit amet aliquam. Phasellus risus libero, varius in condimentum vel, commodo id ipsum. Aliquam in metus cursus, mattis diam ut, aliquam magna. Suspendisse facilisis dui et orci varius, suscipit facilisis augue dapibus. In eget nibh ipsum. Suspendisse eget pharetra est, quis condimentum felis. Fusce scelerisque congue libero, sed aliquam mi elementum a. Etiam scelerisque ante non auctor porta. Nam eu nunc id ex finibus dictum. Praesent dui ex, dictum ac massa eget, rutrum gravida nisi.
Sed egestas arcu in dui euismod, eget faucibus massa iaculis. Etiam efficitur lectus et purus lobortis, ac blandit eros rutrum. Proin bibendum consectetur leo vel gravida. Etiam et ultricies sapien. Nam lacinia tellus erat, id facilisis est consequat et. Morbi quis risus in neque iaculis pharetra ut consectetur libero. Aenean feugiat tempor mi eu posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer gravida non felis non euismod. Fusce finibus aliquet consequat. Nam ac metus bibendum, iaculis purus sed, suscipit ligula. Proin et nisi libero. Mauris non urna urna. Nullam augue eros, fringilla sed mauris vitae, porta tincidunt risus. Aliquam sed tincidunt sem. Quisque lacinia quam tortor, imperdiet efficitur odio iaculis in. Sed ultricies condimentum volutpat. Vivamus dignissim faucibus porta.
Curabitur ut ipsum non odio malesuada vulputate. Morbi maximus, est eu lobortis molestie, tortor sapien hendrerit nisi, in cursus odio diam ut odio. Fusce pulvinar volutpat velit. Aliquam erat volutpat. Integer rhoncus mollis suscipit. Praesent non ipsum mollis, finibus nunc a, scelerisque nibh. In feugiat iaculis velit, eu semper lacus dignissim nec. Praesent vitae nisi leo. Cras venenatis dictum magna ut semper. Sed eget eros nibh. Sed vitae quam sed dolor faucibus elementum. Curabitur interdum porttitor finibus. Nullam tincidunt odio lectus, sit amet rhoncus libero dapibus sed. Sed mollis egestas enim, vel porta tortor volutpat eget.
Morbi orci urna, ornare non pretium eget, pulvinar eget magna. Ut consectetur efficitur varius. Fusce ac aliquet mauris, at mattis ligula. Quisque est libero, interdum id orci et, ornare luctus diam. Proin commodo lectus id accumsan blandit. Nulla eu turpis interdum, luctus ante ac, imperdiet tellus. In semper enim eu tristique aliquam.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer gravida non felis non euismod. Fusce finibus aliquet consequat. Nam ac metus bibendum, iaculis purus sed, suscipit ligula. Proin et nisi libero. Mauris non urna urna. Nullam augue eros, fringilla sed mauris vitae, porta tincidunt risus. Aliquam sed tincidunt sem. Quisque lacinia quam tortor, imperdiet efficitur odio iaculis in. Sed ultricies condimentum volutpat. Vivamus dignissim faucibus porta.
Curabitur ut ipsum non odio malesuada vulputate. Morbi maximus, est eu lobortis molestie, tortor sapien hendrerit nisi, in cursus odio diam ut odio. Fusce pulvinar volutpat velit. Aliquam erat volutpat. Integer rhoncus mollis suscipit. Praesent non ipsum mollis, finibus nunc a, scelerisque nibh. In feugiat iaculis velit, eu semper lacus dignissim nec. Praesent vitae nisi leo. Cras venenatis dictum magna ut semper. Sed eget eros nibh. Sed vitae quam sed dolor faucibus elementum. Curabitur interdum porttitor finibus. Nullam tincidunt odio lectus, sit amet rhoncus libero dapibus sed. Sed mollis egestas enim, vel porta tortor volutpat eget.